Lifevantage Corporation (Delaware) (LFVN) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-03, Lifevantage Corporation (Delaware) (NASDAQ: LFVN) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $5.87 (-0.17% 1D, market cap $73.9M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 19/20. Across 1015 tracked Health Care issuers, LFVN ranks #110 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFVN carries a Roarable C+ (67/100 RQD), trailing P/E of 7.5x, gross margin of 80.4%, and ROIC of 29.2%. By comparison, CING (Cingulate Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $73.1M) and CRBP (Corbus Pharmaceuticals Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $75.7M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).
Per LFVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000849146), Lifevantage Corporation (Delaware) generated $228.5M in revenue (+14.2% YoY), $9.8M in net income, and $10.5M in free cash flow against $61.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (80.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)
SEC XBRL FY 2025 (10-K): 4.6% FCF Margin ($10.5M FCF) & 80.4% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
Even with a 67/100 (C+) score, LFVN faces multiple-compression risk if 7.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 77.9% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($6.12) or 200D SMA ($5.88) invalidates the momentum regime and cuts Target Base ($6.11) toward Bear Floor ($4.77).
Lifevantage Corporation (Delaware) (LFVN) slipped -0.17% to $5.87, trading at 25% of its 52-week range ($3.9 – $11.71). Solid 80.4% gross margin (29% return on capital), mixed timing at 8x P/E—hold if owned, no rush to chase.
ProDex (PDEX) delivered earnings and revenue surprises of +37.31% and +0.78%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
SALT LAKE CITY, Oct. 29, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN) continues to lead the next generation of healthy aging with its latest in vitro research study examining how five modern environme
SALT LAKE CITY, Oct. 26, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today annou
CWH, LFVN and CGAU have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2026.
SALT LAKE CITY, Oct. 12, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”) today announced that its Board of Directors granted inducement awards to Terrence Moorehead, the C
Lifevantage (NASDAQ:LFVN) executives outlined a turnaround plan centered on strengthening the company’s brand, improving consumer relevance and increasing operating efficiency during a Water Tower Research conference dis
SALT LAKE CITY, Sept. 18, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today an
Revenue fell 23% as macroeconomic pressures weighed on orders and average order sizes.
Moby summary of LifeVantage Corporation's Q4 2026 earnings call
New CEO outlines turnaround plan as subscription base remains resilient despite macroeconomic headwinds
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +14.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LFVN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LFVN. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Lifevantage Corporation (Delaware) (LFVN) ranks #110 by composite RQD confidence (67/100, grade C+) and #690 by equity capitalization ($73.9M). Within this direct 5-issuer industry benchmark cohort, LFVN leads on earnings valuation at 7.5x trailing P/E, while LFVN leads on capital efficiency and profitability with 29.2% ROIC and 80.4% gross margin. LFVN currently leads its immediate peer cohort in composite quantitative strength at 67/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LFVN
ACTIVE
Lifevantage Corporation (Delaware) | C+ | 67/100 | 7.5x | 80.4% | 29.2% | -0.17% | $73.9M | Benchmark Subject |
| CING Cingulate Inc. | E | 34/100 | — | — | -35.0% | +1.00% | $73.1M | /cing-vs-lfvn → |
| CRBP Corbus Pharmaceuticals Holdings Inc. | E | 34/100 | — | — | -35.0% | -7.23% | $75.7M | /crbp-vs-lfvn → |
| COYA Coya Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -10.53% | $75.8M | /coya-vs-lfvn → |
| RANI Rani Therapeutics Holdings Inc. (Class A) | E | 30/100 | — | — | -35.0% | -6.47% | $76.9M | /rani-vs-lfvn → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), Lifevantage Corporation (Delaware) (LFVN) reported GAAP revenue of $228.5M (+14.2% vs. FY2024 revenue of $200.2M , and +7.1% cumulative change since FY2023) , GAAP net income of $9.8M, operating cash flow of $11.9M, and free cash flow of $10.5M (+5.6% YoY). On the balance sheet, LFVN closed FY2025 with $61.2M in total assets against $0 in total debt (Altman Z-Score: 3.98, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $228.5M | $9.8M | $11.9M | $10.5M | $61.2M | — |
| FY2024 (FY) | 2024-06-30 | $200.2M | $2.9M | $12.2M | $10.0M | $68.5M | — |
| FY2023 (FY) | 2023-06-30 | $213.4M | $2.5M | $6.8M | $6.8M | — | — |
As of 2026-11-03, Lifevantage Corporation (Delaware) (NASDAQ: LFVN) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $5.87 (-0.17% 1D, market cap $73.9M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 19/20. Across 1015 tracked Health Care issuers, LFVN ranks #110 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFVN carries a Roarable C+ (67/100 RQD), trailing P/E of 7.5x, gross margin of 80.4%, and ROIC of 29.2%. By comparison, CING (Cingulate Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $73.1M) and CRBP (Corbus Pharmaceuticals Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $75.7M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).
Per LFVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000849146), Lifevantage Corporation (Delaware) generated $228.5M in revenue (+14.2% YoY), $9.8M in net income, and $10.5M in free cash flow against $61.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (80.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
LFVN last traded at $5.87 (-0.17% on volume of 17,237 shares), positioning the stock -4.08% below its 50-day simple moving average ($6.12) and -0.17% below its 200-day simple moving average ($5.88). Across its 52-week range of $3.90 to $11.71, LFVN sits at the 25.2% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($5.45 to $6.29).
Lifevantage Corporation (Delaware) (LFVN) earns a live Roarable RQD composite score of 67/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $5.87 (-0.17% 1D, market capitalization $73.9M).
Lifevantage Corporation (Delaware) is listed on NASDAQ under ticker LFVN...1B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Lifevantage Corporation (Delaware) (LFVN) reported $228.5M in annual revenue (up from $200.2M in FY2024, +14.2% YoY) and $9.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($213.4M revenue, $2.5M net income) through FY2025, LFVN scaled operating cash flow to $11.9M and free cash flow to $10.5M, backed by $61.2M in total assets against $0 in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), LFVN carries a macro regime beta of 1.00 and gross margin of 80.4%.
Real-time company headlines, analyst actions, and sector developments for Lifevantage Corporation (Delaware) (LFVN) • Click "Debate This Headline" to argue it in the Roar Pit below
ProDex (PDEX) delivered earnings and revenue surprises of +37.31% and +0.78%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
SALT LAKE CITY, Oct. 29, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN) continues to lead the next generation of healthy aging with its latest in vitro research study examining how five modern environme
SALT LAKE CITY, Oct. 26, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today annou
CWH, LFVN and CGAU have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2026.
SALT LAKE CITY, Oct. 12, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”) today announced that its Board of Directors granted inducement awards to Terrence Moorehead, the C
Lifevantage (NASDAQ:LFVN) executives outlined a turnaround plan centered on strengthening the company’s brand, improving consumer relevance and increasing operating efficiency during a Water Tower Research conference dis
SALT LAKE CITY, Sept. 18, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today an
Revenue fell 23% as macroeconomic pressures weighed on orders and average order sizes.
Here is why I am bullish on LFVN here at $5.88: Insider conviction (19/20) and a 14.22% FCF yield at a 6.3 forward P/E suggest strong cash generation is priced cheaply relative to earnings.. Compare LFVN's 5.3% operating margin and 29.2% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $5.59 are getting bought.
@RedlineAuditor Shorting a 5/20 institutional whale-flow stock at $5.88 is dangerous when funds are rotating into Health Care.
Institutional flow scores only 9/20, and cash, debt, and EPS are unreported, leaving the valuation case dependent on a thinly documented balance sheet.. Look at the math on LFVN: paying 7.5x trailing P/E for 29.2% ROIC and 5.3% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $5.17 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: